EMPAPRO 10 TAB

About

Empagliflozin is an oral antidiabetic medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Its primary mechanism of action involves blocking the reabsorption of glucose in the kidneys, leading to an increased excretion of glucose in the urine. This unique approach effectively lowers blood glucose levels independently of insulin secretion or sensitivity, making it a valuable option for managing type 2 diabetes mellitus. Beyond its glucose-lowering capabilities, empagliflozin has demonstrated significant and well-documented cardiovascular and renal benefits. Clinical trials have shown it reduces the risk of cardiovascular death, hospitalization for heart failure, and the progression of chronic kidney disease in patients with type 2 diabetes, offering comprehensive protection.

Uses

• Management of type 2 diabetes mellitus
• Reduction of cardiovascular risk in type 2 diabetes
• Reduction of heart failure hospitalization risk
• Slowing progression of chronic kidney disease

Directions For Use

Take one tablet orally once daily in the morning, with or without food, as directed by your physician.

Benefits

• Lowers blood glucose levels
• Reduces HbA1c
• Provides cardiovascular protection
• Reduces risk of heart failure hospitalization
• Slows kidney disease progression
• May aid in weight reduction

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections
• Increased urination
• Thirst
• Nausea
• Constipation
• Dizziness
• Hypotension (low blood pressure)
• Ketoacidosis (rare but serious)
• Kidney problems (rare)
• Back pain
• Fatigue

Safety Measures

• Alcohol - Limit alcohol intake as it can increase the risk of hypoglycemia or ketoacidosis.
• Pregnancy - Not recommended during the second and third trimesters due to potential renal effects on the fetus. Consult a doctor.
• Breastfeeding - Avoid use during breastfeeding as it is unknown if it passes into breast milk and could harm the infant.
• Liver - Use with caution in severe liver impairment; no specific dosage adjustment usually needed but monitor.
• Kidney - Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²).
• Lung - Generally safe for use in patients with lung conditions; no specific precautions related to lung function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.